Abstract. To analyze the binding requirements of LFA-1 for its two most homologous ligands, ICAM-1 and ICAM-3, we compared the effects of various LFA-1 activation regimes and a panel of anti-LFA-1 mAbs in T cell binding assays to ICAM-1 or ICAM-3 coated on plastic. These studies demonstrated that T cell binding to ICAM-3 was inducible both from the exterior of the cell by Mn 2+ and from the interior by an agonist of the "inside-out" signaling pathway. T cells bound both ICAM ligands with comparable avidity. A screen of 29 anti-LFA-1 mAbs led to the identification of two mAbs specific for the c~ subunit of LFA-1 which selectively blocked adhesion of T cells to ICAM-3 but not ICAM-1. These two mAbs, YTH81.5 and 122.2A5, exhibited identical blocking properties in a more defined adhesion assay using LFA-1 transfected COS cells binding to immobilized ligand. Blocking was not due to a steric interference between anti-LFA-1 mAbs and N-linked carbohydrate residues present on ICAM-3 but not ICAM-1. The epitopes of mAbs YTH81.5 and 122.2A5 were shown to map to the I domain of the LFA-1 o~ subunit. A third I domain mAb, MEM-83, has been previously reported to uniquely activate LFA-1 to bind ICAM-1 (Landis, R. C., R. I. Bennett, and N. . J. Cell Biol. 120:1519-1527. We now show that mAb MEM-83 is not able to stimulate binding of T cells to ICAM-3 over a wide concentration range. Failure to induce ICAM-3 binding by mAb MEM-83 was not due to a blockade of the ICAM-3 binding site on LFA-1. This study has demonstrated that two sets of functionally distinct mAbs recognizing epitopes in the I domain of LFA-1 are able to exert differential effects on the binding of LFA-1 to its ligands ICAM-1, and ICAM-3. These results suggest for the first time that LFA-1 is capable of binding these two highly homologous ligands in a selective manner and that the I domain plays a role in this process.
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T HE integrin lymphocyte function-associated antigen (LFA)~-I mediates adhesion events between leukocytes and a variety of other cell types which express one or more of its ligands, namely interceUular adhesion molecule (ICAM)-I (Simmons et al., 1988; Staunton et al., 1988) , ICAM-2 (Staunton et al., 1989), and ICAM-3 (Fawcett et al., 1992; Vazeux et al., 1992; de Fougerolles et al,, 1993) . The ICAM ligands are members of the immunoglobulin superfamily (IgSF), with ICAM-1 and ICAM-3 displaying particular similarity. Both are composed of five extracellular C2-1ike Ig domains and exhibit ~50% amino acid identity rising to 77 % in the second domain. LFA-1 is a typi-1. Abbreviations used in this paper: APC, antigen-presenting cells; ICAM, intercellular adhesion molecule; IgSE immunoglobulin superfamily; LFA, lymphocyte function-associated antigen; LIB, ligand-induced binding; PdBu, phorbol dibutyrate; VLA, very late antigen.
cal integfin composed of a unique ct subunit (CDlla) (Larson et al., 1989 ) and a common 132 subunit (CD18) (Kishimoto et al., 1987; Law et al., 1987) . The c~ subunit contains a 197-amino acid "inserted" (or "I') domain located between repeated domains 2 and 3. A closely related I domain is present in the other two/32-type integrins, Mac-1 and p150,95, and also two members of the/3~ integrins, very late antigen (VLA)-I and VLA-2 (Corhi et al., 1987 (Corhi et al., , 1988 Ignatius et al., 1990; Takada and Hemler, 1989) . Comparisons of the intron/exon boundaries of p150,95 with the platelet integrin GPllbllla suggest that the I domain has been inserted as an evolutionarily conserved unit into the basic integrin structure (Corbi et al., 1990; Heidenreich et al., 1990) . Similar domains are present in a number of unrelated proteins and the integrin I domains are now recognized as belonging to a larger family of so-called type "A" domain proteins (for review see Colomhatti and Bonaldo, 1991) .
LFA-1 mediates leukocyte adhesion events at diverse stages of the immune response, including adhesion to endothelium and extravasation into inflamed tissues, priming of T cells by antigen presenting cells (APCs) and killing of target cells by effector T cells (for review see Harvey et al., 1993) . The details of which ICAM ligand is used at each of these steps is still unclear, but it is currently thought that ICAMs-1 and -2 are principally required for leukocyte adhesion to endothelium, whereas ICAMs-1 and -3 are involved in formation of APC:T cell couples. During the APC:T cell interaction ICAM-1 appears to be the favored ligand on memory T cells whereas ICAM-3, which is expressed at higher levels on resting T cells, may be initially favored during early stages of primary antigenic responses (de Fougerolles and Springer, 1992) .
LFA-1 is not constitutively avid for ICAM-1 van Kooyk et al., 1989) but rapidly acquires high avidity binding in response to one of three basic types of signals: (1) agonists that trigger a so-called "inside-out" signal in leukocytes, which include phorbol esters or mAbs against other surface receptors, such as CD3, CD2, and CD31 (for review see Pardi et al., 1992) ; (2) changes in the extracellular concentrations of the divalent cations Mg 2+, Mn 2+, and Ca 2+ (Dransfield et al., 1992; Dranstield and Hogg, 1989) ; and (3) special "activating" anti-LFA-1 mAbs which directly induce the ligand-binding conformation on the receptor (Andrew et al., 1993; Landis et al., 1993; Robinson et al., 1992; Keizer et al., 1988) . The activation epitope for one of these mAbs, MEM-83, has been mapped and shown to localize to the I domain, thereby suggesting a regulatory role for this domain in LFA-1 activation. Support for such a role has been provided by the finding that a novel Mac-1 "activation-reporter" epitope is also located in the I domain (Diamond and Springer, 1993) . No information is available on the potential role of the I domain in the binding of ICAM-2 or ICAM-3 by LFA-1.
Stable interaction of LFA-1 with ICAM-1 has been shown to be dependent not only upon stimulation of LFA-1 by agonist but also by prior ligation with ICAM-1, referred to as the "ligand induced binding" (LIB) interaction, which represents a necessary step leading to the full activation of LFA-1 (Cabafias and Hogg, 1993) . A similar event has been identified in the integrin GPl/bRIa, in which case stable binding of ligand fibrinogen was shown to be dependent upon a prior interaction with the RGD motif contained within fibrinogen (Duet al., 1991) . These findings suggest that a common feature of integrin activation may be participation by ligand in acquisition of the high avidity-binding conformarion.
In the present study we have examined whether LFA-1 is able to bind selectively to its most homologous ligands, ICAM-1 and ICAM-3. We demonstrate that two functionally distinct sets of anti-LFA-1 mAbs recognizing epitopes in the I domain are able to exert differential effects on the binding of T cells or LFA-l-transfected COS cells to immobili7ed ICAM-1 and ICAM-3. These results therefore suggest for the first time that LFA-1 is capable of binding selectively to ICAMs-1 and -3 and that the I domain has a role in this process.
Materials and Methods

Preparation of ICAM-1 and ICAM-3-coated Plates
ICAM-1 and ICAM-3 fusion proteins, consisting of the first two extracellulax domains fused to a human IgG1 Fc fragment (ICAM-Fcs) have been previously described (Fawcett et al., 1992) . Each preparation of protein A-Sepharose purified ICAM-Fc was checked for purity by SDS-PAGE analysis and found to migrate as a single band under reducing conditions of 70 kD in the case of ICAM-1 and a diffuse band of between 75-80 kD in the case of ICAM-3. ICAM-3-Fc was degiycosylated at 100 #g/mi in buffer conraining 20 mM phosphate, pH 8.0 plus 25 mM EDTA by sequential incubations for 20 and 16 h at 37°C in the presence of 4 and 2 U/ml N-Olycosidase F (Boehringer-Mannheim, UK). For T cell adh~ion assays, ICAM-Fcs were added at 500 ng/well in PBS to Immulon 1 96-well plates (Dynatech Laboratories Inc., Chantilly, VA). For LFA-1/COS cell assays, ICAM-Fcs were added at 500 ng/well to Immulon 3 plates precoated with 1 #g/well goat-anti-human-Fc Ig (Sigma Chemical Company Ltd., Dorset, U.K.). Plates were coated overnight at 40C and non-specific sites were blocked before the adhesion assay with 2.5% BSA (Fraction V, Sigma) in PBS for 2 h at room temperature. All ICAM-Fc constructs were coated to plates at saturating levels, as determined by ELISA and T cell binding assays.
Monoclonal Antibodies
Anti-LFA-1 ~ subunit mAbs MEM-83 and MEM-94 were generously provided by Dr. V. Horejsi (Prague, Czech Republic), mAb 122.2A5 by Dr. R. Vilella (Barcelona, Spain) and mAb YTH81.5 by Serotec (Oxford, U.K.) (Bazil and Horejsi, 1990; Schmidt, 1989) . Anti-ICAM-1 mAb RR1/1 was a gift from Dr. R. Rothlein (Ridgefleld, CT) (Rothlein et al., 1986) . The remaining mAbs, obtained from Dr. Reinhold Schmidt, were from the Leukocyte Typing Workshop IV (Schmidt, 1989) and included the anti-CDlla mAbs MHM24, 122.2A5, MEM-95, MEM-30, MEM-25, 2F12, F110.22, GRS3, I-roll, MI0, 0501, 25.3.1, 459, YTH 81.5, 1524, TMD3-1, CC5 liT/, and the anti-CD18 mAbs H-52, MHM23, TS1/18, M232, IC11, CLB-54, IB-4, YFC 51.1, YFC 118.3, and GRF1. Purified anti-CDlla mAbs MEM-83, 38 and YTH81.5 were used in T cell adhesion assays at final concentrations of 2-5 #g/ml and in immuno-precipitation assays at 30 #g/ml. mAb 122.2A5 was used as ascitic fluid diluted 1:300 in T cell adhesion assays and at 1:50 in immunoprecipitatiun assays. Purified anti-ICAM-1 .mAb RRI/1 was used in T cell binding assays at 10 #g/ml and the imrmmoprecipitation negative control CD8 mAb 14 was used at 30/~g/ml. All other CDlla and CD18 mAbs were used as ascitic fluids in T cell adhesion assays at saturating concentrations ranging between 1:100 and 1:1,000 dilutions depending on FACS titre.
T Cell Adhesion Assay
Human T cells were expanded in culture from unstimulated peripheral blood mononuclear cells and served as a model for inducible adhesion to immobilized ICAM-1 as previously described (Dransfield et ai., 1992) . Briefly 5 × 107 cultured T cells were labeled with 25 #Ci [3H]methyl thymidine and washed three times in the appropriate essay medium supplemented with 0.2% BSA (Fraction V, Sigma). The medium employed in the binding assay was either RPMI 1640 or a defined Mn2+-containing medium, consisting of 20 mM Hepes, 140 mM NaC1, 2 mg/mi D-giucose, and 400 #M Mn 2+. 3H-labeled T cells were added to ICAM-Fc-coated plates in the presence or absence of phorbol dibutyrate 0MBu; 200 nM) at 2.5 x 105 cells/well in a I00-#1 vol. Cells were preincubated on ice for 20 rain in the presence of saturating titres of anti-LFA-1 mAbs in a 50-#1 vol, centrifuged at 30 g for 1 rain and incubated an additional 30 min at 37°C. ICAM-3 binding was carried out in the presence of mAb RRM1 (5 ~tg/ml) to eliminate LFA-1/ICAM-1 dependent clustering of T cells. Cells that remained bound to ICAM-Fc plates after 5 washes with prewarmed RPMI were lysed and the incorporated radioactivity quantitated using a Betaplate counter (LKB Instruments Inc., Bromma, Sweden). Stimulation index is defined as: Cell binding in the presence of agonist (IMBu or Mn2+)/binding in the absence of agonist.
LFA-1 Transfection of COS Cells and Adhesion Assay
COS cells were maintained in D-MEM medium supplemented with 10% FCS and passnged at confluence by trypsinization. COS cells were transiently transfected by DEAE Dextrun using CD1 la and CD18 cDNAs cloned into the expression vector PeDNA/AMP (In Vitrogen, U.K.). Briefly, COS cells were grown to confluence in 15-cm petri dishes and transfected with 50 #g of each cDNA for 2-4 h at 37°C in the presence of 1 mg/ml DEAE dextran, followed by a 2-rain shock in 10% DMSO. LFA-1 transfected COS ceils were used in adhesion assays 48 h after transfection and were routinely 20% LFA-1 positive by FACScan analysis (Becton Dickinson Immuno-cytometry Systems, Mountain View, CA). The adhesion assay was performed similarly as described for T cells. Briefly, LFA-1/COS cells were labeled overnight with [3H]methyl thymidine at 25 #Ci per 2 x 107 cells and harvested before the adhesion assay by ice-cold PBS supplemented with 2 mM EDTA. Cells were washed three times in assay medium, consisting of RPMI supplemented with 2.5% FCS, and added to ICAM-F,c plates in a 30-#1 vol at 3 x 104 cells/well. Cells were preincubated on ice for 20 rain in the presence of 50 ng/ml PMA and saturating titres of anti-LFA-1 mAbs in a 25-/zl vol, followed by an additional 30-rain incubation at 37°C. Cells that remained bound after five washes with prewarmed RPMI were lysed and counted for incorporation of radioactivity as described above.
cDNA Constructs of the LFA-1 ~ Subunit
The construction of the CD1 la deletion series used for epitope mapping has been previously described . The "nested" series of constructs contained successive domain deletions starting from the NH2 terminus of the LFA-1 c~ subunit, with each fragment terminating in domain 7 (designated as fragments N, 2, I, 3 and 4). Thus, the construct spanning from the NH2 terminus to domain 7 was labeled N, the construct spanning from domain 2 to 7 was labeled 2, and so on. A control fragment, which included the region between the end of domain 7 and the transmembrane domain, was designated C. A previously undescfibed fragment, which consisted only of the I domain plus domain 2 (amino acids 71-323), was designated 2-I. PCR amplifications were carded out using a GeneAmp TM DNA amplification kit with Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT) according to the manufacturer's instructions.
In Vitro-Translation and Immunoprecipitation
Transcription and translation of the nested CDlla eDNA deletion series was carried out using the one-step TNT TM T7 coupled reticulocyte lysate system (Promega Corp., Madison, WI) according to manufacturer's instructions. 1/~g of cloned DNA in Bluescript TM KS + phagemid served as the template for the reaction, which was carried out for 2 h at 30°C, in a 50-#1 vol in the presence of [35S]methionlne (Amersham) and rabbit reticulocyte lysate (50% by volume). After translation, 25 ttl of2x EIA buffer (500 mM NaC1, 100 mM Hepes pH 7.0, 0.2% NP-40) was added to an equal volume of translation product and the total volume of the precipitation made up to 200 itl with lx EIA buffer. The primary incubation was carded out in the presence of 30 #g purified mAbs at 4°C for 3-5 h, before the addition of 20/zl (packed volume) Sepharose Protein G beads. Immunoprecipitations were incubated an additional 3-5 h at 4°C before harvesting the Sepharose beads by a 30-s microcentrifugation. 10 #1 of the supernate was removed for monitoring of the translation efficiency of each fragment by SDS-PAGE. The remaining lysate was discarded and the beads washed three times with lx EIA buffer plus 0.1% NP-40, and twice with lx EIA buffer alone. Approximately 25 #1 of electrophoresis reducing buffer was added to the beads before SDS-PAGE analysis on a 9% acrylamide separating gel. Gels were treated with ENHANCE TM (New England Nuclear Research Products, Boston, MA) before autoradiography.
Results
Comparative Binding of T Cells to ICAM-1 and ICAM-3
To determine whether ICAM-3 was recognized by LFA-1 in the same regulated manner as ICAM-1, we examined the effect of two LFA-l-activation regimes on T cell binding to immobilized ICAM-1 and ICAM-3. In these experiments, the high affinity conformation of LFA-1 was triggered either from the. exterior of the cell by the addition of Mn 2+ (Dransfield et al., 1992) or from the interior of the cell by the addition of PdBu, an agonist of the inside-out pathway of LFA-1 activation (Rothlein et al., 1986) . Fig. 1 shows that ICAM-1 and ICAM-3 supported comparable levels of T cell adhesion stimulated through PdBu or Mn 2+. The index of stimulation was also equivalent between the two ligands, with an average stimulation index of 2.9 for ICAM-1 and 3.1 for ICAM-3. These results demonstrate that LFA-1 exhibited the same basic features of avidity-regulation towards its two most homologous ligands, ICAM-1 and ICAM-3.
Effect of anti-LFA-1 mAbs on Adhesion to ICAM-1 and ICAM-3
To determine whether LFA-1 could recognize ICAM-1 and ICAM-3 differentially, we screened a panel of anti-LFA-1 mAbs (consisting of 19 mAbs against the t~ subunit and 10 against the ~2 subunit) for blocking effects on T cell binding to either ligand. In this assay, T ceils were preincubated with the anti-LFA-1 mAbs indicated in Fig. 2 , followed by a 30-min binding step in the presence of PdBu to immobilized ICAM-1 or ICAM-3. Although the blocking footprint of the mAb panel was broadly similar for each of the ligands, the screen identified two mAbs specific for the o~ subunit of LFA-1 which exhibited differential blocking between the two ligands. These two mAbs, YTH 81.5 'and 122.2A5, specifically inhibited T cell binding to ICAM-3 but not ICAM-1 (Fig. 2) .
Having screened the panel of mAbs for selective effects on T cell adhesion to ICAMs-1 and -3, we subsequently examined the blocking properties of mAbs YTH81.5 and 122.2,45 in greater detail. To exclude donor variability, Fig. 3 a was compiled from eight different donors and confirmed that these mAbs exhibited good blocking of T cells to ICAM-3 compared to a control blocking mAb 38, but no blocking to ICAM-1. Selective blocking was maintained under conditions which raised the affinity of LFA-1, using 3 mM Mg 2÷ and 1 mM EGTA (to chelate Ca2+), alone or in combination with phorbol ester (data not shown). These T cell assays, however, suffered from a potential drawback related to the high levels of expression of both ICAM-1 and ICAM-3 
Effect of Deglycosylation on ICAM-3 Ligand Function
ICAM-3 is an extensively glycosylated molecule which expresses five potential N-linked glycosylation sites on domain 1 which are absent from the corresponding region of ICAM4 (Fawcett et al., 1992; Vazeux et al., 1992; de Fougerolles et al., 1993) . It is therefore possible that anti-LFA-1 mAbs YTH81.5 and 122.2A5 could be mediating their selective blocking effects indirectly, via a steric interaction with bulky carbohydrate residues present on ICAM-3 but not ICAM-1. To address this issue directly and to gain further insight into the role of glycosylation on ligand function, ICAM-3 was deglycosylated at the asparagine glycosylamine linkage by treatment with N-Glycosidase E Fig 
Mapping of the YTH81.5 and 122.2A5 Epitopes
To identify regions within the extracellular domain of the LFA-1 ce subunit that might be involved in the blocking of ICAM-3 binding, we mapped the epitopes of YTH81.5 and 122.2A5. This was accomplished by immunoprecipitation of in vitro-translated protein fragments of the LFA-1 ce subunit. A eDNA deletion series of the LFA-1 ce subunit was constructed, which consisted of five successive single domain deletions beginning from the NH2-end and terminating in domain 7 (each fragment labeled according to its NH2 terminus as N, 2, I, 3, 4), plus a control fragment (C) which included the rest of the ce subunit terminating at the transmembrane domain (see Materials and Methods). Radiolabeled proteins corresponding to these constructs were immunoprecipitated by the anti-LFA-1 mAbs of interest or an irrelevant anti-CD8 mAb (mAb 14) and resolved by SDS-
Effect of mAb MEM-83 on ICAM-1 vs ICAM-3 Binding
We have previously identified a unique LFA-1 activation epitope, recognized by mAb MEM-83, which is also located in the I domain of the LFA-1 ot subunit . It was therefore of interest to determine whether this mAb could induce binding of LFA-1 to ICAM-3 in a manner similax to that previously reported for ICAM-1. Fig. 6 demonstrates that mAb MEM-83 was not able to stimulate binding of T cells to ICAM-3 over a wide concentration range, in contrast to the induced binding to ICAM-1. Although differential binding to ICAM-1 in the presence of mAb MEM-83 might be due to selective effects on the LFA-1 activation process, it is equally possible that it is simply due to blocking by mAb of the ICAM-3 binding site on LFA-1. To test this latter possibility, mAb MEM-83 was assessed for its ability to inhibit binding of LFA-1 to ICAM-3 when LFA-1 was activated via another stimulus. Fig. 7 shows that mAb MEM-83 does not block Mn2+-induced binding to either ICAM-1 or ICAM-3, while reiterating the fact that it could selectively induce de novo binding to ICAM-1. These results demonstrate that mAb MEM-83 can influence LFA-1 activation in favor of ICAM-l-binding in the absence of any intrinsic ICAM-3 blocking properties. Taken in conjunction with the selective blocking properties of mAbs YTH81.5 and 122.235, these results with mAb MEM-83 demonstrate that epitopes exist within the I domain of LFA-1 which can regulate the binding to different ICAM ligands. PAGE. The upper panel of Fig. 5 a demonstrates that mAbs YTHS1.5 and 122.2A5 immunoprecipitated protein fragments which contained the I domain (fragments N, 2 and I), but not fragments from which the I domain had been deleted (3, 4, and C). Nonspecific binding by the control mAb 14 was minimal. The lower panel of Fig. 5 a represents the nonprecipitated fraction and shows that efficiency of translation and incorporation of radiolabel within each protein fragment was comparable across the entire deletion series. Although in vitro translation generated truncated protein fragments, only full length translation products (marked by an arrow) were immunoprecipitated. To provide further evidence that the I domain was sufficient for recognition by these mAbs, the LFA-1 ~x subunit was deleted from the COOH-terminal end of the I domain, creating a fragment consisting only of the I domain plus domain 2 (2-I). Fig. 4 b demonstrates that mAb YTH81.5 could recognize this construct, thereby confirming that it mapped to the I domain of LFA-1.
Discussion
We have demonstrated that the integrin LFA-1 can bind selectively to its two most homologous ligands, ICAM-1 and ICAM-3, and that the I domain has a critical role in this process. The experimental approach was to screen a panel of anti-LFA-1 mAbs for differential effects on T cell binding to ICAM-1 vs ICAM-3. By this means, we identified three mAbs specific for the c~ subunit of LFA-1 which allow discrimination of LFA-1 binding to ICAM-1 and ICAM-3. mAb MEM-83 induced LFA-1 to bind ICAM-1 but not ICAM-3, whereas mAbs YTHS1.5 and 122.2A5 exhibited selective blocking of ICAM-3. Differential blocking was confirmed in an independent adhesion assay which employed LFA-1-transfected COS cells binding to immobilized ligand. Importantly, the COS cell assay was free from any possible interference by cell surface ICAMs. This was relevant because the T cells used in our studies expressed cell-surface ICAM-1 and ICAM-3 at equivalent levels (data not shown).
A trivial explanation for the selective blocking effects by mAbs YTH81.5 and 122.235 might be invoked if the affinity of LFA-I is greater for ICAM-1 than for ICAM-3, in which case binding to the latter ligand might be more easily blocked. Several facts argue against this possibility. Firstly, such differential inhibition was not observed with any other mAbs studied in the panel. Secondly, avidity of binding to ICAM-1 and ICAM-3 was comparable using either activated T cells or LFA-l-transfected COS cells. These results confirm a previous observation that T cells are able to bind ICAM-1 and ICAM-3 with comparable avidity (Campanero et al., 1993) but are not in accordance with an earlier report that ICAM-1 is the favored ligand for LFA-1 (de Fougerolles and Springer, 1992) . Apparent differences could depend on a number of distinctive factors between the adhesion assays employed in these studies, such as cell type, source of ICAM-3, activation regimes and inversion of the binding assay (i.e., binding of ICAM-expressing cells to immobilized LFA-1). It should be noted that none of these adhesion assays are suitable for obtaining monomolecular affinities between receptor/ligand pairs and that such a determination for ICAM-1 and ICAM-3 will require competition and equilibrium binding experiments of the type used to measure the affinity constant for mouse LFA-1 to ICAM-1 (Lollo et al., 1993) .
ICAM-3 contains five potential asparagine-linked glycosylation sites in domain 1 which are absent from the corresponding domain of ICAM-1. As the LFA-1 binding site of ICAM-3 has been localized to domain 1 and part of domain 2 (Holness, C., manuscript submitted for publication), it could be argued that mAbs YTH81.5 and 122.2A5 might be artefactually preventing access to the binding site via a steric interaction with bulky carbohydrate residues selectively expressed on domain 1 of ICAM-3. To address this possibility, ICAM-3 Fc was deglycosylated by treatment with N-Glycosidase F, which has previously been shown to remove asparagine-linked oligosaccharides under non-denaturing conditions from a variety of proteins (Tarentino et al., 1985) . The resultant deglycosylated ICAM-3Fc retained reactivity with a panel of 14 mAbs specific for the first two domains of ICAM-3 and still supported binding of LFA-1 expressed on T cells. These results suggest that the extensive glycosylation on domain 1 is not essential for maintaining conformation or ligand function of ICAM-3. The ability of deglycosylated ICAM-3 to support binding of LFA-1 was similar to results obtained using ICAM-1 (data not shown) and a previous report on ICAM-1 ligand function (Diamond et al., 1991) . Furthermore, experiments using deglycosylated ICAM-3 ligand ruled out carbohydrates as possible mediators of the selective blocking effects by anti-LFA-1 mAbs YTHS1.5 and 122.2A5.
The third anti-LFA-1 mAb MEM-83 selectively induced binding of T cells to ICAM-1 but not ICAM-3, which provided a second line of evidence that binding of LFA-1 to these two ligands was distinct. Again there are several possible explanations as to how this mAb might be working. One possibility is that mAb MEM-83-activated cells failed to bind ICAM-3 simply because the mAb blocked the high affinity ICAM-3 binding site. This was not the case, however, as MEM-83 did not block the LFA-1/ICAM-3 interaction when the high affinity state of LFA-1 was induced by Mn 2+. An alternative possibility is that mAb MEM-83 could be exerring its effects at an earlier phase of the LFA-1/ICAM interaction. The high affinity phase of ICAM-1 binding is dependent not only upon agonist stimulation of LFA-1 but also a preceding ligation with ICAM-1 via the so-called "LIB" interaction, which represents a necessary step leading to the full activation of LFA-1 (Cabafias and Hogg, 1993) . It is not yet certain whether the LIB interaction with ICAM-1 is required to stabilize a transiently activated LFA-1 conformer or whether ICAM-1 directly induces a higher affinity state of LFA-1. Thus, mAb MEM-83 could be directly inducing/stabilizing an active ICAM-1 binding conformer of LFA-1 or alternatively preventing the alteration necessary for ICAM-3 binding or both. A similar argument may also be applied to explain the selective blocking effects of mAbs YTH81.5 and 122.2A5. The role of LIB interactions with ICAM-3 in the LFA-1 activation process is currently under investigation.
There are examples in other systems of differential binding by one integrin of multiple ligands. For example, VLA-2 exhibits cell-type specific adhesion towards ligands collagen and laminin (Elices and Hemler, 1989; Kirchhofer et al., 1990) and VLA-4 can bind the IgSF ligand VCAM-1 and the CS1 region of fibronectin depending on the cellular context in which they are expressed (Elices et al., 1990) . These binding patterns can be influenced not only by the local cell environment but also by treatment with divalent cations and activating mAbs (Chan and Hemier, 1993; Matsumoto and Hemler, 1993) . In contrast, the present results suggest that recognition of the two IgSF ligands ICAM-1 and ICAM-3 by Finally, epitope mapping studies revealed that the two ICAM-3-inhibiting mAbs YTH81.5 and 122.2A5 and the LFA-1 activating rnAb MEM-83 all map to the I domain of the LFA-1 ct subunit. Based on competition binding experiments, the three mAbs appeared to recognize a cluster of closely related epitopes (data not shown). All three mAbs can recognize a recombinant I domain fusion protein, which was also shown to contain a ligand binding site for ICAM-1 (Randi and Hogg, 1994 ). An attractive speculation would be that alternative forms of the LFA-1-binding site exist normally on the cell surface after activation and that rnAbs used in this study are able to induce/stabilize (MEM-83) or interfere with (YTHS1.5 and 122.2A5) one of these forms. Function-affecting mAbs to the I domain may therefore be directly influencing the ligand binding site within this domain.
